Sutro Biopharma(US:STRO)2021-04-15 23:25Company Strategy & Technology - Sutro Biopharma is expanding cell-free technology beyond ADCs, building strategic partnerships, and creating new modalities for extended value creation[8] - The company utilizes an industry-leading cell-free protein synthesis platform with GMP production yields consistent and scalable end-products[12] - Sutro's cell-free synthesis platform allows for the creation of hundreds of protein variants in weeks, enabling empirical selection of the best lead candidate[18] STRO-002 Program (Ovarian and Endometrial Cancers) - STRO-002 is a FolRα-targeting ADC with a DAR of 4, designed with a potentially dual mechanism of action[28] - In a Phase 1 dose-escalation study, 34 patients were treated at clinically active doses (≥ 2.9 mg/kg Q3W) of STRO-002[30] - In the RECIST-evaluable population (N=31), 10 patients met the criteria for response, with an objective response rate of 20%[36] - Clinical benefit was observed in a heavily pre-treated patient population, with a disease control rate of 74% at 12 weeks in the RECIST-evaluable population[43] STRO-001 Program (Lymphomas and Multiple Myeloma) - STRO-001 is a CD74-targeting ADC with a DAR of 2, designed to minimize bystander effects in hematological cancers[57] - In the NHL cohort, a total of 21 patients have been treated with STRO-001, and 18 patients were evaluable for response as of October 30, 2020[62] - Interim data showed partial responses in two DLBCL patients who had progressed on CAR-T therapy[67] Financial Status - The company reported $326.5 million in cash, cash equivalents, and marketable securities as of year-end 2020[73] - The projected cash runway extends into 2H 2023, not including potential monetization of Vaxcyte shares or future business development[73] - Sutro Biopharma has received approximately $398 million in funding from collaborators through year-end 2020[73]